Response of basal and pentagastrin-stimulated gastric secretion and of serum gastrin to short- and long-term intravenous infusion of salmon calcitonin in hyperchlorhydric subjects

Effect of calcitonin on the interdigestive motility and on gastric and pancreatic secretion in humans

Calcitonin given in doses (0.2 and 1 MRC U/kg-1h-1) reproducing the levels observed in medullary carcinoma of the thyroid, induced the appearance of phase III type activity and reduced the duration of the IMC in the small intestine from 123 to 87 min with 0.2 MRC U kg-1h-1 and from 123 to 43 min with 1 MRC U kg-1h-1 but not in the stomach of young volunteers. This increase in phase III-like activity occurred despite a sharp reduction in motilin levels. Only the highest dose of calcitonin reduced significantly acid secretion (by more than 90%) while both doses reduced amylase secretion by respectively 65 and 71% when compared to the control levels. These changes in motility and secretion could partly explain the diarrhea observed in patients with the medullary carcinoma of the thyroid.

Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro

Omeprazole has been previously shown to block gastric acid secretion by specific inhibition of gastric parietal cell membrane H+-K+-ATPase. It is now demonstrated that similar concentrations of omeprazole will inhibit PGE2- and PTH-stimulated 45Ca++ release from prelabelled neonatal mouse calvariae without affecting the viability of cultured calvaria explants.